ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.